<<Two 600 pts pivotal placebo and active drug controlled completed. Highly statistical significant, positive and negative symptoms, no safety issue! >>
My god what a unfortunate - and disgustingly, sophmorically personal -reaction to what I considered quite positive comments to the TTP data. I will revise my wording to indicate the patient poulation was more than adequate for the scope of PII and PIII. I will reiterate my points, said up front and prominently, that Zomaril is likely to be a 'significant improvement versus current antipsychotic regimens', and 'strongly suggesting a win/win scenario: a reduction in both positive and negative symtomology together with substantially fewer extrapyramidal, cardiac, weight-related etc. contaminating factors. '
But PII and preliminary PIII data is just that.
I did my graduate work with someone who was just entering the schizophrenia field and thus doing a substantial literature compilation. The field is fraught with reports of 'wonder drugs' only to be shown to be applicable to a restricted sub-group of the effected population subsequent to approval for broad use.
And this <<Right! In your dream!>> crap! What the hell is that? Where the hell are you coming from anyway? Describe to me your training - or that of Rick Harmon for that matter - in neurobiology and thus having the proper background and perspective to judge schizophrenia pharmacology. I guess it's irrelevent to dilineate the 5-HT versus the DA synaptic chemistry in order to understand this relatively new class of of atypical antipsychotics. Do you even understand what make these a 'new class' in the first place or is the science irrelevant?
In short, I gave high praise for the promise of Zomaril. However, with a much clearer understanding of the history of antipsychotics than you display, I was logically and rationally hesitant to be blindly gangbusters about the data (like yourself) until a much broader population sampling is achieved.
And what the hell is this Ariad 'baying' nonsense? For someone who has 'Many semi-favorite, only one true love... REGN, REGN and only REGN' in their profile, you've got incredible nerve! What a friggin' hypocrite! And what about Rick Harmon's astute 'baying' of Gliatech (talk about a short!)? Your collective hubris is off-scale.
And I challenge you to compare the publication records of Ariad and Regeneron. Not even close...but oops! I forgot...the science doesn't count (and it also doesn't count that I'm on public record on SI that I sold about 98% of my ARIA holdings about 6 months ago...but why in the <expletive deleted> should I have to explain this to YOU??).
Are we supposed to be AFRAID of everyone Rick Harmon makes friends with? Are we supposed cower under the likelihood, no the certainty, that Rick sends more PMs than Dear Abby ever would write to assure complete compliance with his view of 'acceptable' participants in SI biotech forums? Is everyone outside his 'clique' open to absurd broadsides like you just unleashed while the 'insiders' are protected? What is this, the SI version of the Balkans??? Do you always follow so closely Rick Harmon's coattails, Miljenko, and do you remind him (and yourself) at every opportunity of the incredible 'baying' you two do of your own pet stocks?
I can't believe the tone and the personal nature of your post - obviously based on encouragement from Rick Harmon - since we've had few, if any, exchanges in the past. If I misrepresented the number of patients that were appropriate for this stage of Zomaril's development, fine. I deserve to be corrected...in a dignified and intelligent manner. That's what SI is all about. Your tone was, and is, unnecessary especially since it reeks of the paradox that you have no training whatsoever in the Neurosciences. GO FIGURE THAT ONE!
(but there I go again letting that silly Science creep into the text).
No one on SI (or anywhere else) would or should put up with your tone; I can promise you your tone and approach will be met in kind.
Scott |
